Skip to content

Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03977259
Enrollment
130
Registered
2019-06-06
Start date
2020-01-31
Completion date
2030-12-31
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Development Abnormality, Breast Milk Expression, Neurodevelopmental Disorders, Nutrition Disorder, Infant, Preterm Birth

Brief summary

This study is a randomized trial comparing 2 methods of human milk fortification for preterm infants in the neonatal intensive care unit (NICU). All participating infants will receive a human milk diet comprising maternal and/or donor milk plus multi-component and modular fortifiers. In one group (control), the milk will be fortified according to routine standard of care. In the other group (intervention), the fortification will be individually targeted based on the results of point-of-care human milk analysis. Outcomes include physical growth in the NICU and after discharge, brain structure by magnetic resonance imaging at term equivalent age, and neurodevelopment at 2 years.

Detailed description

Human milk is the recommended diet for preterm infants and it requires fortification to meet their high nutrient requirements. This study addresses a gap in knowledge about the optimal strategy for human milk fortification in the neonatal intensive care unit (NICU). Infants will be recruited from a single site (Brigham and Women's Hospital, Boston MA). Eligible infants are NICU inpatients born \<31 weeks' gestation and enrolled within 21 days of birth, whose mothers are providing breast milk. Exclusion criteria include major congenital anomalies, severe fetal growth restriction (weight \<3rd percentile), clinically significant gastrointestinal pathology, triplets or higher order multiples, and expected death or transfer. Infants who require fluid restriction \<140 mL/kg/day will also be excluded. The study period begins when infants have reached full volume (150-160 mL/kg/day) human milk feedings fortified to 24 kcal per ounce. Participants will be randomized to one of two diet groups; twins will be randomized separately. The study diet will continue until 36 weeks' postmenstrual age or hospital discharge, whichever comes first. Available maternal milk will be pooled with donor milk (if needed) to reach the total daily fluid volume; this "base" milk will be analyzed with a point-of-care human milk analyzer (Miris, AB). All infants will receive at minimum the standard human milk fortification (multicomponent fortifier to 24 kcal/oz plus liquid protein 0.27 g/dL). In one group (control), we will follow the standard of care for milk fortification, only adding more protein and/or energy if weight gain is lagging. In the other group (intervention), we will individually target fortification with additional protein and/or energy so that the "base" milk always contains protein 1 g/dL and energy 67 kcal/dL. Outcome measures will include physical growth during the diet intervention period, including gain in weight, length, and head circumference and body composition with air displacement plethysmography at the end of the diet intervention. At term equivalent age, participants will undergo brain magnetic resonance imaging. At 2 years corrected age, outcomes include standard and novel neurodevelopmental tests including the Bayley-III and tests of emerging executive function; and physical size.

Interventions

OTHERIndividually targeted fortification

Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the "base" milk has protein 1 g/dL and calories 67/dL.

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Parents, clinical, and research staff apart from the study milk technician will be unaware of the treatment group.

Eligibility

Sex/Gender
ALL
Age
1 Days to 21 Days
Healthy volunteers
No

Inclusion criteria

* Inpatient in Brigham and Women's Hospital NICU * Gestational age 24 0/7 to 30 6/7 weeks * Chronologic age \<21 days * Mother providing breast milk

Exclusion criteria

* Major congenital anomaly * Severe fetal growth restriction (birth weight \<3rd percentile by Olsen reference) * Necrotizing enterocolitis, intestinal perforation, other major gastrointestinal pathology * Triplets or higher order multiples * Plan for redirection of care and/or anticipated death * Clinically significant renal or hepatic dysfunction * Inborn error of metabolism * Fluid restriction \<140 mL/kg/day for 3 or more days * Grade 3 or 4 intraventricular hemorrhage detected prior to enrollment * Anticipated transfer \<36 weeks' postmenstrual age * Parents do not consent to use of pasteurized donor human milk * Infant in non-parental custody

Design outcomes

Primary

MeasureTime frameDescription
Weightat study endpoint (36 weeks' postmenstrual age or discharge)Weight z-score
Lengthat study endpoint (36 weeks' postmenstrual age or discharge)Length z-score
Fat free massat study endpoint (36 weeks' postmenstrual age or discharge)Fat free mass estimated with air displacement plethysmography (z-score)
Total brain volumeat term equivalent age (38 to 41 weeks' postmenstrual age)Total brain volume by MRI
Cerebellar volumeat term equivalent age (38 to 41 weeks' postmenstrual age)Cerebellar volume by MRI
Bayley-III cognitive scoreat 2 years' corrected ageScaled composite score (continuous), higher score indicates better performance, range of possible scores 55-145
Bayley-III motor scoreat 2 years' corrected ageScaled composite score (continuous), higher score indicates better performance, range of possible scores 46-154

Secondary

MeasureTime frameDescription
Fat massat study endpoint (36 weeks' postmenstrual age or discharge)Fat mass estimated with air displacement plethysmography (z-score)
Weightat 2 years' corrected ageWeight z-score
Heightat 2 years' corrected ageHeight z-score
Low Bayley-III cognitive scoreAt 2 years' corrected ageScaled composite score \<85 (\>1 standard deviation below the normative mean)
Low Bayley-III motor scoreAt 2 years' corrected ageScaled composite score \<85 (\>1 standard deviation below the normative mean)
Bayley-III language scoreAt 2 years' corrected ageScaled composite score (continuous), higher score indicates better performance, range of possible scores 46-154
Spacial working memoryat 2 years' corrected ageSpin the Pots task (number of trials, search time)
Behavioral inhibitionat 2 years' corrected ageMommies and Babies task (number of trials, errors)
Executive functionat 2 years' corrected ageBehavioral Rating Inventory of Executive Function - Preschool Version, higher scores indicate more problems
Behavioral difficultiesat 2 years' corrected ageInfant-Toddler Symptom Checklist - Long Version, higher scores indicate more problems

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMandy B Belfort, MD, MPH

Brigham and Women's Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026